Form 4 for SUPN SUPERNUS PHARMACEUTICALS, INC.
Accepted 2026-02-25 00:00:00 ET · period of report 2026-02-24 · accession 0001745316-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-25 | 2026-02-24 | SUPN | Barlow Carrolee | Dir | A - Grant | $0.00 | +4,475 | 27.0K | +20% | $0 |
| D | 2026-02-25 | 2026-02-24 | SUPN | Barlow Carrolee | Dir | D - Sale to Iss | $0.00 | -4,475 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-24 | A | A | 4,475 | $0.00 | 27,045 | D | — | — | |
| 2 | Derivative | Restricted Stock Unit | 2026-02-24 | D | D | 4,475 | $0.00 | 0 | D | — · — to — | 4,475 Common Stock | (F1) Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. (F2) These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026. |